<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771368</url>
  </required_header>
  <id_info>
    <org_study_id>CTP 7</org_study_id>
    <nct_id>NCT00771368</nct_id>
  </id_info>
  <brief_title>Reduction of Bacteria in MRSA Positive Ulcers</brief_title>
  <official_title>A Clinical Trial on the Reduction of Bacteria (Including MRSA) in MRSA Positive Ulcers and Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if gaseous nitric oxide is effective in the&#xD;
      treatement of bacteria in MRSA positive ulcers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    limited recruitment&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in bacteria</measure>
    <time_frame>Post Treatment Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leg Ulcer</condition>
  <condition>Pressure Ulcer</condition>
  <arm_group>
    <arm_group_label>Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gaseous nitric oxide delivered topically for 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days</description>
    <arm_group_label>Nitric Oxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have given written informed consent&#xD;
&#xD;
          -  Must be 19 years of age or over&#xD;
&#xD;
          -  Must have an ulcer or lesion in which the presence of MRSA has been positively&#xD;
             identified but which is not clinically infected.&#xD;
&#xD;
          -  Must have an Ulcer / Lesion size not to extend beyond the inner borders of the wound&#xD;
             cover&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a female who is pregnant, nursing, or of child bearing potential who is not using&#xD;
             an adequate form of contraception (or abstinence)&#xD;
&#xD;
          -  Is &lt; 19 years of age&#xD;
&#xD;
          -  Has a clinically infected ulcer&#xD;
&#xD;
          -  Has an Ulcer / Lesion that is currently treated or has been treated with a topical&#xD;
             antimicrobial agent during 3 days prior to enrolment.&#xD;
&#xD;
          -  Has been using systemic antibiotics during 7 days prior to enrolment into this study.&#xD;
&#xD;
          -  Has an Ulcer / Lesion which is identified as malignant in origin (e.g., Marjolin's&#xD;
             ulcer)&#xD;
&#xD;
          -  Has an Ulcer / Lesion size beyond the inner borders of the wound cover&#xD;
&#xD;
          -  Is septic or has other signs of an invasive infection&#xD;
&#xD;
          -  Has used any other investigational product within 30 days preceding study&#xD;
             participation.&#xD;
&#xD;
          -  Suffers from a condition, which, in the opinion of the Investigator,would compromise&#xD;
             his or her safety.&#xD;
&#xD;
          -  Suffers from a condition which, in the opinion of the Investigator, would compromise&#xD;
             the quality of the data.&#xD;
&#xD;
          -  Has a known allergy to any of the products that are part of this protocol&#xD;
&#xD;
          -  Suffers from a condition which, in the opinion of the Investigator, would seriously&#xD;
             interfere negatively with the normal parameters of immune response to an infection.&#xD;
&#xD;
          -  Is using any of the prohibited concomitant medications or treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>President &amp; CEO</name_title>
    <organization>Nitric BioTherapeutics, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

